ReviewInternational journal of medical sciences2026
The Potential Connection Between Mechanical Stress and Heart Failure with Preserved Ejection Fraction: Mechanistic Insights and Therapeutic Potential.
Review in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) represents a complex clinical syndrome characterized by limited therapeutic options, which are largely due to its intricate pathophysiology. The role of mechanical stress is pivotal in maintaining cardiovascular homeostasis; conversely, its dysregulation may precipitate the progression of cardiovascular diseases. In HFpEF, both macroscopic structural alterations and intricate molecular processes might be influenced by mechanical stress. This review examines the potential associations between mechanical stress and HFpEF, exploring the pathophysiological underpinnings to the effects of mechanotransduction effectors on cardiac remodeling and the progression of heart failure, providing novel insights into the pathological mechanisms of HFpEF. Therapeutic strategies targeting these mechanotransduction effectors have shown promise in mitigating pathological cardiac remodeling in models of metabolic-associated heart failure, underscoring their potential as innovative treatments for HFpEF. Considering the clinical heterogeneity of HFpEF, it is imperative to pursue phenotype-specific personalized treatments to optimize therapeutic efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.